CT26.CL25細(xì)胞
數(shù)量： 大量
器官來源： 結(jié)腸
是否是腫瘤細(xì)胞： 0
物種來源： 小鼠
細(xì)胞形態(tài)： 成纖維樣
運(yùn)輸方式： 凍存運(yùn)輸
品系： BALB/c
ATCC Number： CRL-2639?
相關(guān)**： 腫瘤
生長狀態(tài)： 貼壁生長
Designations: CT26.CL25
Depositors: N Restifo
CT26.CL25細(xì)胞Biosafety Level: 2 [Cells contain SV40 viral DNA sequences ]
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Mus musculus deposited as mouse
Morphology: fibroblast
Source: Organ: colon
Strain: BALB/c
Disease: carcinoma
Cellular Products: beta galactosidase (beta-gal) [53315]
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes
Antigen Expression: H-2d [53315]
Comments: CT26 is an N-nitroso-N-methylurethane-(NNMU) induced, undifferentiated colon carcinoma cell line. It was cloned to generate the cell line designated CT26.WT (ATCC CRL-2638).
CT26.WT was stably transduced with the retroviral vector LXSN that contains the lacZ gene encoding the model tumor associated antigen (TAA), beta-galactosidase (beta-gal). CT26.CL25細(xì)胞[53315]
The vector is driven by the Moloney murine leukemia virus (MoMuLV) long terminal repeat (LTR) promoter and contains a gene controlling resistance to neomycin transcribed from the SV40 promoter.
The cells were grown in G418 for seven days, cloned, and evaluated for beta-gal production. [53315]
The lethal subclone CT26.CL25 (ATCC CRL-2639) was selected for use in all in vitro and in vivo studies because of its stable high expression of both beta-gal and the class I molecule H-2 Ld. [53315]
The growth rate and lethality of CT26.CL25 and CT26.WT is virtually identical despite the expression by CT26.CL25 of the model TAA, beta-galactosidase, in normal mice. [53315]
The cell line can be used as a model for testing immunotherapy protocols and in studies on the host immune response.
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES and 1.0 mM sodium pyruvate and supplemented with 0.1 mM non-essential amino-acids and 0.4 mg/ml G418, 90%; fetal bovine serum, 10%
Temperature: 37.0°C
Subculturing: Protocol: Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subculture at 80% confluence. Cells pile up and do not become completely confluent.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Related Products: CT26.CL25細(xì)胞Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
parental cell line:ATCC CRL-2638
References: 53315: Wang M, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154: 4685-4692, 1995. PubMed: 7722321
56139: Chen PW, et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156: 224-231, 1996. PubMed: 8598466
56140: Irvine KR, et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156: 238-245, 1996. PubMed: 8598468
56141: Carroll MW, et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15: 387-394, 1997. CT26.CL25細(xì)胞PubMed: 9141209
